← Back to patent-cliff list
Ambroxol Hydrochloride/Salbutamol sulfate
Tier C — Watch / tradeAmbroxol Hydrochloride/Salbutamol sulfate
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：SCNA, ADRB2
Indications (approved)：Asthma, Chronic obstructive pulmonary disease, Chronic bronchitis, Bronchospasm, Bronchitis
Regional status
US
-
EU
-
China
Phase III
2013-11-20
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Ambroxol Hydrochloride/Salbutamol sulfate?
Approved indications include: Asthma, Chronic obstructive pulmonary disease, Chronic bronchitis, Bronchospasm, Bronchitis.
When does the Ambroxol Hydrochloride/Salbutamol sulfate patent expire?
No public expiry year is available for Ambroxol Hydrochloride/Salbutamol sulfate yet; this page updates once verified.
How do I get a quote for Ambroxol Hydrochloride/Salbutamol sulfate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-12